| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,547 |
6,024 |
$1.47M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
11,328 |
10,636 |
$962K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,531 |
3,921 |
$578K |
| 80053 |
Comprehensive metabolic panel |
17,697 |
13,793 |
$294K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
2,581 |
2,062 |
$270K |
| 59025 |
Fetal non-stress test |
1,961 |
1,118 |
$235K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
1,246 |
970 |
$224K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,469 |
2,087 |
$211K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
5,981 |
5,564 |
$155K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
2,558 |
2,419 |
$152K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,590 |
2,128 |
$132K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
22,830 |
16,954 |
$131K |
| 71046 |
Radiologic examination, chest; 2 views |
7,211 |
6,168 |
$99K |
| 36415 |
Collection of venous blood by venipuncture |
16,572 |
12,279 |
$90K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
9,040 |
6,672 |
$88K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
9,598 |
4,458 |
$76K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
1,004 |
721 |
$70K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,129 |
955 |
$65K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
4,530 |
3,276 |
$63K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,521 |
1,427 |
$48K |
| 84484 |
|
6,624 |
4,009 |
$41K |
| 71045 |
Radiologic examination, chest; single view |
6,004 |
4,693 |
$40K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
937 |
825 |
$38K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,826 |
1,114 |
$36K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
5,138 |
4,279 |
$32K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
879 |
778 |
$29K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,101 |
2,881 |
$29K |
| 81001 |
|
10,306 |
8,664 |
$28K |
| 86901 |
|
1,242 |
986 |
$25K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
121 |
93 |
$24K |
| 81025 |
|
3,165 |
2,799 |
$22K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
525 |
499 |
$21K |
| 87088 |
|
2,505 |
2,122 |
$20K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,846 |
1,523 |
$20K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
852 |
438 |
$20K |
| 83690 |
|
3,550 |
2,851 |
$19K |
| 94760 |
|
1,427 |
868 |
$19K |
| 87400 |
|
2,951 |
1,517 |
$17K |
| 87081 |
|
2,575 |
2,378 |
$17K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
517 |
257 |
$17K |
| 82962 |
|
3,404 |
1,604 |
$16K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
107 |
91 |
$14K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,539 |
1,255 |
$13K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
921 |
140 |
$13K |
| 81003 |
|
4,955 |
4,185 |
$12K |
| 87186 |
|
2,126 |
1,773 |
$11K |
| 76801 |
|
324 |
297 |
$11K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,736 |
1,331 |
$10K |
| 87040 |
|
1,098 |
670 |
$9K |
| 85610 |
|
3,075 |
2,318 |
$8K |
| 73630 |
|
375 |
307 |
$8K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
337 |
311 |
$7K |
| 87077 |
|
901 |
781 |
$7K |
| 83880 |
|
457 |
352 |
$7K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
261 |
114 |
$7K |
| 83605 |
|
865 |
634 |
$6K |
| 87807 |
|
746 |
703 |
$6K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
57 |
40 |
$6K |
| 72141 |
|
34 |
25 |
$6K |
| 74018 |
|
325 |
249 |
$6K |
| 86710 |
|
313 |
295 |
$6K |
| 73610 |
|
404 |
323 |
$5K |
| 72100 |
|
277 |
248 |
$5K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
4,512 |
3,149 |
$5K |
| 87420 |
|
524 |
427 |
$5K |
| 73560 |
|
276 |
216 |
$5K |
| 86900 |
|
1,237 |
982 |
$5K |
| 85730 |
|
1,377 |
1,063 |
$5K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
46 |
37 |
$5K |
| 93976 |
|
122 |
92 |
$4K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
466 |
443 |
$4K |
| 80061 |
Lipid panel |
967 |
750 |
$4K |
| A9270 |
Non-covered item or service |
7,785 |
1,622 |
$4K |
| 83735 |
|
1,103 |
734 |
$4K |
| 71020 |
|
284 |
260 |
$4K |
| 76642 |
|
165 |
140 |
$4K |
| 80320 |
|
310 |
266 |
$3K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
847 |
620 |
$3K |
| 73130 |
|
167 |
133 |
$3K |
| J2785 |
Injection, regadenoson, 0.1 mg |
34 |
26 |
$3K |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
67 |
45 |
$3K |
| 87070 |
|
174 |
156 |
$3K |
| 84702 |
|
335 |
251 |
$3K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,792 |
1,358 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
220 |
210 |
$3K |
| 97161 |
|
98 |
69 |
$3K |
| 86850 |
|
436 |
340 |
$2K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
182 |
169 |
$2K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
160 |
122 |
$2K |
| 81002 |
|
633 |
447 |
$2K |
| 77066 |
Tomosynthesis, mammo |
41 |
37 |
$2K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
34 |
33 |
$2K |
| 80050 |
General health panel |
52 |
46 |
$2K |
| 73030 |
|
114 |
96 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
486 |
323 |
$2K |
| 82077 |
|
136 |
111 |
$2K |
| 77065 |
Tomosynthesis, mammo |
44 |
40 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
502 |
393 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
803 |
434 |
$2K |
| G0378 |
Hospital observation service, per hour |
435 |
241 |
$2K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
67 |
42 |
$2K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
13 |
13 |
$2K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
57 |
40 |
$1K |
| 84443 |
Thyroid stimulating hormone (TSH) |
635 |
523 |
$1K |
| 93017 |
|
75 |
53 |
$1K |
| 80305 |
|
107 |
89 |
$1K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
13 |
12 |
$1K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
73 |
39 |
$1K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
30 |
24 |
$1K |
| T1015 |
Clinic visit/encounter, all-inclusive |
100 |
63 |
$924.37 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,665 |
2,076 |
$775.60 |
| 73110 |
|
48 |
37 |
$697.77 |
| 85027 |
|
157 |
117 |
$644.49 |
| 96376 |
|
269 |
128 |
$622.03 |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
19 |
13 |
$594.24 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
3,082 |
1,789 |
$552.25 |
| 87486 |
|
16 |
12 |
$551.32 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
3,046 |
2,001 |
$488.91 |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
32 |
24 |
$484.50 |
| 71010 |
|
73 |
58 |
$461.21 |
| 82803 |
|
36 |
26 |
$442.08 |
| 80143 |
|
28 |
26 |
$385.65 |
| 73562 |
|
16 |
12 |
$385.00 |
| 85007 |
|
116 |
97 |
$361.15 |
| 82553 |
|
45 |
26 |
$346.08 |
| 72040 |
|
19 |
14 |
$326.62 |
| 73502 |
|
12 |
12 |
$301.28 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
388 |
203 |
$293.55 |
| 87210 |
|
54 |
52 |
$262.30 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
197 |
111 |
$260.71 |
| 90715 |
|
14 |
12 |
$259.20 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
802 |
487 |
$246.16 |
| 84703 |
|
34 |
26 |
$233.09 |
| 82947 |
|
175 |
71 |
$206.00 |
| 87205 |
|
26 |
24 |
$199.11 |
| 97165 |
|
19 |
13 |
$197.76 |
| J2704 |
Injection, propofol, 10 mg |
671 |
400 |
$155.26 |
| 85379 |
|
31 |
24 |
$130.77 |
| 87158 |
|
33 |
25 |
$126.24 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
713 |
398 |
$102.46 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
88 |
66 |
$101.12 |
| J2060 |
Injection, lorazepam, 2 mg |
163 |
129 |
$94.74 |
| 82150 |
|
18 |
16 |
$83.34 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
88 |
66 |
$41.40 |
| 82607 |
|
16 |
13 |
$21.52 |
| J3490 |
Unclassified drugs |
130 |
103 |
$16.65 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
38 |
25 |
$13.90 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
15 |
14 |
$11.07 |
| J7510 |
Prednisolone oral, per 5 mg |
24 |
20 |
$2.64 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
46 |
39 |
$0.74 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
14 |
13 |
$0.02 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
13 |
12 |
$0.01 |
| 29799 |
|
55 |
31 |
$0.00 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
22 |
12 |
$0.00 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
309 |
149 |
$0.00 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
18 |
15 |
$0.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
166 |
141 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
14 |
12 |
$0.00 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
45 |
26 |
$0.00 |
| J7050 |
Infusion, normal saline solution, 250 cc |
21 |
17 |
$0.00 |